Mirrors of Medicine
@mirrorsofmedicine.bsky.social
Open, multidisciplinary platform facilitating access to unique #CME programmes w/ focus on improving clinical decision making. Both online & offline.
European Association of Urology Guidelines on Muscle-invasive and Metastatic #BladderCancer : Summary of the 2025 Guidelines
www.europeanurology.com/article/S030...
Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols
www.europeanurology.com/article/S030...
Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
This overview of the 2025 European Association of Urology guidelines offers valuable
insights into the risk factors, diagnosis, classification, treatment, and follow-up
of muscle-invasive bladder canc...
www.europeanurology.com
May 22, 2025 at 8:25 AM
European Association of Urology Guidelines on Muscle-invasive and Metastatic #BladderCancer : Summary of the 2025 Guidelines
www.europeanurology.com/article/S030...
Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols
www.europeanurology.com/article/S030...
Recommendations reflects regulatory changes, such as the removal of sacituzumab govitecan, and presents updated follow-up protocols
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single...
Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising
antitumour activity, supporting further evaluation of this chemotherapy-free triplet
regimen.
www.thelancet.com
May 21, 2025 at 8:26 AM
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with HR+, HER2+ metastatic #BreastCancer
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
www.thelancet.com/journals/lan...
Results support further investigation of this chemotherapy-free triplet approach as a potential tx option
@erikahamilton9.bsky.social
Advancing breast cancer treatment in the era of molecular diagnostics
thebreastonline.com/article/S096...
Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]
thebreastonline.com/article/S096...
Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]
Advancing breast cancer treatment in the era of molecular diagnostics
Advances in cancer biology and drug development now enable treatments tailored to
individual tumor profile. Targeting specific molecular alterations, marking a significant
step forward in cancer care,...
thebreastonline.com
May 20, 2025 at 6:17 PM
Advancing breast cancer treatment in the era of molecular diagnostics
thebreastonline.com/article/S096...
Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]
thebreastonline.com/article/S096...
Recent advances in #BreastCancer treatment have shifted toward personalized, biomarker-driven approaches that leverage molecular diagnostics to guide therapy selection. ]
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive #BreastCancer
link.springer.com/article/10.1...
Findings suggest that prolonged NET may lead to more substantial tumor downstaging
link.springer.com/article/10.1...
Findings suggest that prolonged NET may lead to more substantial tumor downstaging
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer - Breast Cancer Research and Treatment
Purpose Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant e...
link.springer.com
May 19, 2025 at 1:47 PM
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive #BreastCancer
link.springer.com/article/10.1...
Findings suggest that prolonged NET may lead to more substantial tumor downstaging
link.springer.com/article/10.1...
Findings suggest that prolonged NET may lead to more substantial tumor downstaging
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer
www.nature.com/articles/s43...
Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer
www.nature.com/articles/s43...
Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial - Nature Cancer
Galsky and colleagues report the results of a phase 1 clinical trial of anti-programmed cell death protein 1 ligand 1 atezolizumab in combination with PGV001, a personalized neoantigen vaccine, in par...
www.nature.com
May 9, 2025 at 11:33 AM
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial OUT ON nature Cancer
www.nature.com/articles/s43...
Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer
www.nature.com/articles/s43...
Trial met its primary endpoints, supporting the feasibility and safety of this approach, and suggesting it warrants further investigation. #BladderCancer
Reposted by Mirrors of Medicine
NEWS FROM INDUSTRY
Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...
Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...
May 9, 2025 at 9:54 AM
NEWS FROM INDUSTRY
Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...
Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer
www.astrazeneca.com/media-centre...
Addition of zoledronic acid to enzalutamide and ADT in metastatic hormone-sensitive prostate cancer: BONENZA
www.nature.com/articles/s41...
Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response
www.nature.com/articles/s41...
Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial - Prostate Cancer and Prostatic Dise...
Prostate Cancer and Prostatic Diseases - Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II...
www.nature.com
May 8, 2025 at 9:52 AM
Addition of zoledronic acid to enzalutamide and ADT in metastatic hormone-sensitive prostate cancer: BONENZA
www.nature.com/articles/s41...
Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response
www.nature.com/articles/s41...
Study confirmed that ZA did not enhance treatment efficacy in this setting, though WB-DW-MRI proved a reliable tool for monitoring bone metastasis response
PALMIRA: Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With HR+/HER 2– Advanced #BreastCancer
ascopubs.org/doi/full/10....
Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.
ascopubs.org/doi/full/10....
Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents
the standard first-line treatment for patients with hormone receptor–positive/human
epidermal growth f...
ascopubs.org
May 7, 2025 at 9:27 AM
PALMIRA: Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With HR+/HER 2– Advanced #BreastCancer
ascopubs.org/doi/full/10....
Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.
ascopubs.org/doi/full/10....
Ultimately, the trial did not demonstrate a significant benefit of palbociclib rechallenge over ET alone in this setting.
2L Endocrine Therapy With or Without Palbociclib Rechallenge in HR+/Human Epidermal Growth Factor Receptor 2–Negative Advanced #BreastCancer: PALMIRA Trial
ascopubs.org/doi/full/10....
Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.
ascopubs.org/doi/full/10....
Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents
the standard first-line treatment for patients with hormone receptor–positive/human
epidermal growth f...
ascopubs.org
May 6, 2025 at 9:29 AM
2L Endocrine Therapy With or Without Palbociclib Rechallenge in HR+/Human Epidermal Growth Factor Receptor 2–Negative Advanced #BreastCancer: PALMIRA Trial
ascopubs.org/doi/full/10....
Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.
ascopubs.org/doi/full/10....
Overall, palbociclib rechallenge did not significantly improve outcomes over ET alone in this setting.
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early #BreastCancer 🇩🇰
sciencedirect.com/science/arti...
Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy
sciencedirect.com/science/arti...
Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
Clinical prediction models are increasingly used to guide treatment in patients with early breast cancer. The Danish Breast Cancer Group (DBCG) has de…
sciencedirect.com
May 2, 2025 at 4:33 PM
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early #BreastCancer 🇩🇰
sciencedirect.com/science/arti...
Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy
sciencedirect.com/science/arti...
Findings validate PSI as a useful tool for risk-adapted treatment allocation, supporting its role in sparing low-risk patients unnecessary chemotherapy
Stereotactic Body Radiation☢️Therapy Alone or in Combination with Immunotherapy in #KidneyCancer
sciencedirect.com/science/arti...
findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.
sciencedirect.com/science/arti...
findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.
Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review
Despite its radioresistant reputation, renal cell carcinoma (RCC) is sensitive to high dose per fraction stereotactic ablative body radiotherapy (SABR…
sciencedirect.com
April 15, 2025 at 2:44 PM
Stereotactic Body Radiation☢️Therapy Alone or in Combination with Immunotherapy in #KidneyCancer
sciencedirect.com/science/arti...
findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.
sciencedirect.com/science/arti...
findings underscore the need for large, randomized trials to further evaluate SABR’s potential, particularly in metastatic settings.
Clinical characteristics & prognostic factors in pts with breast cancer and leptomeningeal metastases
www.thebreastonline.com/article/S096...
Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation
www.thebreastonline.com/article/S096...
Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC
Leptomeningeal metastases (LM) in patients with breast cancer (BC) are associated
with a dismal prognosis. We explored clinical characteristics and prognostic factors
in patients with BC and LM in the...
www.thebreastonline.com
April 4, 2025 at 9:23 AM
Clinical characteristics & prognostic factors in pts with breast cancer and leptomeningeal metastases
www.thebreastonline.com/article/S096...
Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation
www.thebreastonline.com/article/S096...
Highlight need for optimized treatment strategies & suggest clinicopathological factors can aid in selecting candidates for tx escalation or de-escalation
Selective Elimination of Breast Surgery for Invasive #BreastCancer out on JAMA Oncology
jamanetwork.com/journals/jam...
Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.
jamanetwork.com/journals/jam...
Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.
Selective Elimination of Breast Surgery for Invasive Breast Cancer
This nonrandomized trial examines 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients with breast cancer selected with image-guided vacuum assisted biopsy.
jamanetwork.com
April 3, 2025 at 7:52 AM
Selective Elimination of Breast Surgery for Invasive #BreastCancer out on JAMA Oncology
jamanetwork.com/journals/jam...
Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.
jamanetwork.com/journals/jam...
Findings suggest that in carefully selected cases, surgery may not be necessary, though further studies are needed to confirm this approach before changing standard practice.
Correlation analysis of invasive disease-free survival and OS in a real-world population of patients w/ HR+/HER2– early #BreastCancer
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting
Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer
This study analyzed the correlation of invasive disease-free survival (iDFS) and overall survival (OS) in the adjuvant HR+/HER2– early breast cancer (EBC) setting using real-world patient data. The r....
acsjournals.onlinelibrary.wiley.com
March 31, 2025 at 9:21 AM
Correlation analysis of invasive disease-free survival and OS in a real-world population of patients w/ HR+/HER2– early #BreastCancer
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Results support iDFS as clinically meaningful & reliable 1ry endpoint assessing tx benefit in this setting
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma
jamanetwork.com/journals/jam...
Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval.
#KidneyCancer
jamanetwork.com/journals/jam...
Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval.
#KidneyCancer
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma
This cohort study of US adults with metastatic clear cell renal cell carcinoma examines changes in forms of treatment used following the approval of immune-checkpoint inhibitor combinations by the US ...
jamanetwork.com
March 26, 2025 at 3:48 PM
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma
jamanetwork.com/journals/jam...
Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval.
#KidneyCancer
jamanetwork.com/journals/jam...
Results revealed a shift from tyrosine kinase inhibitor (TKI) monotherapy, previously the most common first-line therapy, to ICI-based combinations following their approval.
#KidneyCancer
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial #BreastCancer
thegreenjournal.com/article/S016...
thegreenjournal.com/article/S016...
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
Immune checkpoint inhibitors (ICI) have been investigated in combination with preoperative
chemotherapy in early-stage triple negative breast cancer (TNBC) and in estrogen receptor-positive,
human epi...
thegreenjournal.com
March 21, 2025 at 2:16 PM
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial #BreastCancer
thegreenjournal.com/article/S016...
thegreenjournal.com/article/S016...
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians
sciencedirect.com/science/arti...
Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer
sciencedirect.com/science/arti...
Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians
The treatment landscape for patients with advanced urothelial carcinoma (UC) has evolved rapidly in recent years. In current guidelines, combination t…
sciencedirect.com
March 20, 2025 at 10:37 AM
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians
sciencedirect.com/science/arti...
Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer
sciencedirect.com/science/arti...
Physicians and patients should engage in shared decision-making, considering the benefit-risk balance of each option. #BladderCancer
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
nature.com/articles/s41...
model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer
nature.com/articles/s41...
model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial - Nature Communications
Angioscore is a transcriptome based predicter of treatment response in clear cell renal cell carcinoma. Here, the authors use deep learning to infer the Angioscore from histopathology slides using cli...
nature.com
March 19, 2025 at 5:53 PM
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
nature.com/articles/s41...
model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer
nature.com/articles/s41...
model showed strong correlation with the Angioscore and was effective in predicting AA response in real-world and clinical trial cohorts. #KidneyCancer
Body composition as a potential biomarker of recurrence risk in patients with triple-negative #BreastCancer
link.springer.com/article/10.1...
Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR
link.springer.com/article/10.1...
Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR
Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer - Breast Cancer Research and Treatment
Background Triple-negative breast cancer (TNBC) patients are at increased risk for recurrence compared to other subtypes of breast cancer. Previous evidence showed that adiposity may contribute to wor...
link.springer.com
March 14, 2025 at 12:01 PM
Body composition as a potential biomarker of recurrence risk in patients with triple-negative #BreastCancer
link.springer.com/article/10.1...
Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR
link.springer.com/article/10.1...
Findings suggest that VSR may serve as a stronger prognostic biomarker than BMI, with potential implications for future interventions aimed at reducing VSR
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
ascopubs.org/doi/full/10....
The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients
ascopubs.org/doi/full/10....
The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
PURPOSEThe COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab
in advanced solid tumors. Presented here are results from the expansion cohorts with
advanced urothelial ...
ascopubs.org
March 11, 2025 at 1:43 PM
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
ascopubs.org/doi/full/10....
The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients
ascopubs.org/doi/full/10....
The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients
Safety & Efficacy of Neoadjuvant Durvalumab + Gemcitabine/Cisplatin or Carboplatin in Patients W/ Operable High-Risk Upper Tract Urothelial Carcinoma
ascopubs.org/doi/10.1200/...
Although the primary endpoint was not met, the combination therapy showed promising downstaging effects
#BladderCancer
ascopubs.org/doi/10.1200/...
Although the primary endpoint was not met, the combination therapy showed promising downstaging effects
#BladderCancer
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial
PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC),
prognosis is poor for high-risk patients. This study evaluated safety and efficacy
of neoadjuvant chemotherap...
ascopubs.org
March 10, 2025 at 12:43 PM
Safety & Efficacy of Neoadjuvant Durvalumab + Gemcitabine/Cisplatin or Carboplatin in Patients W/ Operable High-Risk Upper Tract Urothelial Carcinoma
ascopubs.org/doi/10.1200/...
Although the primary endpoint was not met, the combination therapy showed promising downstaging effects
#BladderCancer
ascopubs.org/doi/10.1200/...
Although the primary endpoint was not met, the combination therapy showed promising downstaging effects
#BladderCancer
Reposted by Mirrors of Medicine
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
March 7, 2025 at 1:25 PM
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
March 7, 2025 at 1:25 PM
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
www.tandfonline.com/doi/full/10....
This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes.
#KidneyCancer
www.tandfonline.com/doi/full/10....
This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes.
#KidneyCancer
STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with im...
www.tandfonline.com
March 6, 2025 at 12:16 PM
STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
www.tandfonline.com/doi/full/10....
This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes.
#KidneyCancer
www.tandfonline.com/doi/full/10....
This is the first phase III trial evaluating a TKI-ICI combination in nccRCC across multiple subtypes.
#KidneyCancer
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
February 25, 2025 at 11:29 AM
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer